DK1411916T3 - Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd - Google Patents

Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd

Info

Publication number
DK1411916T3
DK1411916T3 DK02748104T DK02748104T DK1411916T3 DK 1411916 T3 DK1411916 T3 DK 1411916T3 DK 02748104 T DK02748104 T DK 02748104T DK 02748104 T DK02748104 T DK 02748104T DK 1411916 T3 DK1411916 T3 DK 1411916T3
Authority
DK
Denmark
Prior art keywords
methods
men
materials
testosterone deficiency
treating
Prior art date
Application number
DK02748104T
Other languages
Danish (da)
English (en)
Inventor
Joseph S Podolski
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23175972&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1411916(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Application granted granted Critical
Publication of DK1411916T3 publication Critical patent/DK1411916T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK02748104T 2001-07-09 2002-07-09 Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd DK1411916T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US30431301P 2001-07-09 2001-07-09
PCT/US2002/021524 WO2003005954A2 (en) 2001-07-09 2002-07-09 Methods and materials for the treatment of testosterone deficiency in men

Publications (1)

Publication Number Publication Date
DK1411916T3 true DK1411916T3 (da) 2008-12-15

Family

ID=23175972

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02748104T DK1411916T3 (da) 2001-07-09 2002-07-09 Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd

Country Status (24)

Country Link
US (6) US7759360B2 (es)
EP (1) EP1411916B1 (es)
JP (2) JP4845165B2 (es)
KR (1) KR100851648B1 (es)
CN (2) CN1954807A (es)
AT (1) ATE406153T1 (es)
AU (1) AU2002318225B2 (es)
BR (1) BR0211067A (es)
CA (2) CA2453337C (es)
CL (1) CL2004000026A1 (es)
CO (1) CO5550428A2 (es)
CY (1) CY1108563T1 (es)
DE (1) DE60228583D1 (es)
DK (1) DK1411916T3 (es)
EC (1) ECSP044937A (es)
ES (1) ES2312593T3 (es)
HK (1) HK1071521A1 (es)
MX (1) MXPA04000097A (es)
NZ (2) NZ551013A (es)
PL (1) PL211339B1 (es)
PT (1) PT1411916E (es)
RU (1) RU2297218C2 (es)
WO (1) WO2003005954A2 (es)
ZA (1) ZA200400142B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7737185B2 (en) * 2001-07-09 2010-06-15 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene
BR0211067A (pt) 2001-07-09 2006-10-31 Zonagen Inc métodos e materiais para o tratamento de deficiência de testosterona em homens
US7173064B2 (en) 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
MX2007000050A (es) * 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
CA2595363C (en) * 2005-02-04 2012-03-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
US8247456B2 (en) * 2005-03-22 2012-08-21 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
US20080312239A1 (en) * 2007-06-13 2008-12-18 Quatrx Pharmaceuticals Company Methods for the treatment of erectile dysfunction using fispemifene
US20110118355A1 (en) * 2007-09-21 2011-05-19 Harry Fisch Treatment of migraine headaches using antiestrogens
MY150082A (en) 2007-10-16 2013-11-29 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
WO2009052377A1 (en) * 2007-10-18 2009-04-23 Harry Fisch Treatment of migraine headaches using antiestrogens
US20090215738A1 (en) * 2008-02-26 2009-08-27 Michael Charles Scally Prevention and treatment of an increase in cardiovascular risk, adverse cardiovascular events, infertility, and adverse psychological effects after androgen or gnrh analogue intake
TWI477276B (zh) 2008-04-28 2015-03-21 Repros Therapeutics Inc 抗黃體素給藥方案
RU2474424C2 (ru) * 2010-09-24 2013-02-10 Государственное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гиперэстрадиолемии и нормогонадотропного гипогонадизма у мужчин
UA113291C2 (xx) 2011-08-04 2017-01-10 Метаболіти транскломіфену і їх застосування
WO2013020215A1 (en) * 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males
NZ702467A (en) 2012-05-31 2016-07-29 Repros Therapeutics Inc Formulations and methods for vaginal delivery of antiprogestins
SG10201704820SA (en) * 2012-08-21 2017-07-28 Repros Therapeutics Inc Trans-clomiphene formulations and uses thereof
AU2013338311A1 (en) 2012-11-02 2015-05-14 Repros Therapeutics Inc. Trans-clomiphene for use in cancer therapy
CA2888377C (en) 2012-11-02 2021-02-02 Repros Therapeutics Inc. Methods and compositions for treating progesterone-dependent conditions
US9814687B2 (en) * 2014-08-20 2017-11-14 Professional Compounding Centers Of America Transdermal pharmaceutical compositions including C-SERMs for low testosterone levels in men
RU2586305C1 (ru) * 2015-02-02 2016-06-10 Государственное бюджетное образовательное учреждение высшего профессионального образования "Ивановская государственная медицинская академия" Министерства здравоохранения Российской Федерации Способ лечения обструктивной азооспермии и криптозооспермии у пациентов с хроническим простатитом
EP3368506B1 (en) 2016-04-22 2023-09-06 F.I.S.- Fabbrica Italiana Sintetici S.p.A. Process for the preparation of enclomiphene citrate having needle shaped crystal habit.

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2914563A (en) * 1957-08-06 1959-11-24 Wm S Merrell Co Therapeutic composition
IT951631B (it) 1971-03-18 1973-07-10 Richardson Merrell Spa Composti utili per la separazione di isomeri ottici geometrici e strutturali e relativo procedimen to di sintesi
US4061733A (en) * 1976-10-15 1977-12-06 Narayan Vishwanath Gunjikar Veterinary compositions for inducing estrus in animals and method
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
ATE36312T1 (de) 1985-06-08 1988-08-15 Asta Pharma Ag Neue derivate des 1,1,2,2-tetramethyl-1,2-bis-(2fluor-4-hydroxyphenyl)-ethans.
US4820736A (en) * 1987-03-20 1989-04-11 Yale University Use of clomiphene to predict fertility in a human female
GB8926171D0 (en) 1989-11-20 1990-01-10 Applied Research Systems Treatment of infertility
JPH04312522A (ja) 1991-04-08 1992-11-04 Yoshiaki Kawashima 徐放性錠剤の製造方法
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
GB9405304D0 (en) * 1994-03-16 1994-04-27 Scherer Ltd R P Delivery systems for hydrophobic drugs
US5650425A (en) * 1994-04-04 1997-07-22 Pharmos Corporation Permanently ionic derivatives of steroid hormones and their antagonists
EP0802787A4 (en) 1994-06-17 1998-09-02 Univ Nebraska VECTOR FOR DELIVERY OF BIO-EFFECTIVE SUBSTANCES WITH GELLIFICATION -i (IN SITU) AND METHOD OF USE
DE4435368A1 (de) * 1994-09-22 1996-03-28 Schering Ag Verwendung von Aromatasehemmern zur Herstellung eines Arzneimittels zur Behandlung eines relativen Androgenmangels beim Mann
DE69617245T2 (de) * 1995-08-17 2002-07-25 Csir Pretoria Produkte mit gesteuerter freisetzung
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
AU744156B2 (en) * 1996-10-28 2002-02-14 General Mills Inc. Embedding and encapsulation of controlled release particles
US6322797B1 (en) * 1997-04-03 2001-11-27 Guilford Pharmaceuticals, Inc. Biodegradable terephthalate polyester-poly (phosphate) polymers, compositions, articles, and methods for making and using the same
US6653297B1 (en) * 1997-07-03 2003-11-25 Medical College Of Hampton Roads Control of selective estrogen receptor modulators
US6342250B1 (en) * 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
US6413533B1 (en) 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6291505B1 (en) * 1998-08-07 2001-09-18 Chiron Corporation Estrogen receptor modulators
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
TWI281398B (en) * 1999-06-11 2007-05-21 Watson Pharmaceuticals Inc Administration of non-oral androgenic steroids to women
CA2321321A1 (en) * 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6258802B1 (en) 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
WO2001052823A2 (en) * 2000-01-20 2001-07-26 Noven Pharmaceuticals, Inc. Compositions to effect the release profile in the transdermal administration of drugs
JP2003534375A (ja) * 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
JP2004507465A (ja) * 2000-08-11 2004-03-11 ワイス エストロゲン受容体陽性癌腫の治療方法
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20040192598A1 (en) 2000-10-11 2004-09-30 Laura Kragie Composition and method of alleviating adverse side effects and/or enhancing efficacy of agents that inhibit aromatase
CA2431566A1 (en) * 2000-12-11 2002-07-18 Testocreme, Llc Topical testosterone formulations and associated methods
BR0211067A (pt) 2001-07-09 2006-10-31 Zonagen Inc métodos e materiais para o tratamento de deficiência de testosterona em homens
US7173064B2 (en) * 2001-07-09 2007-02-06 Repros Therapeutics Inc. Methods and compositions with trans-clomiphene for treating wasting and lipodystrophy
US6645974B2 (en) * 2001-07-31 2003-11-11 Merck & Co., Inc. Androgen receptor modulators and methods for use thereof
EP1429779A2 (en) 2001-09-21 2004-06-23 Merck & Co., Inc. Androstanes as androgen receptor modulators
US6600110B1 (en) * 2001-10-01 2003-07-29 Gram Precision Portable digital readout scale
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US7105679B2 (en) * 2001-12-19 2006-09-12 Kanojia Ramesh M Heteroatom containing tetracyclic derivatives as selective estrogen receptor modulators
JP4312522B2 (ja) 2003-06-30 2009-08-12 株式会社リコー 現像剤補給方法、現像剤補給装置、及び、画像形成装置
MX2007000050A (es) 2004-07-14 2007-07-10 Repros Therapeutics Inc Trans-clomifeno para el tratamiento de hipertrofia de prostata benigna, cancer de prostata, hipogonadismo, trigliceridos elevados y colesterol elevado.
CA2595363C (en) 2005-02-04 2012-03-27 Repros Therapeutics Inc. Methods and materials with trans-clomiphene for the treatment of male infertility
JP2008537538A (ja) * 2005-02-11 2008-09-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Ｖｅｇｆ拮抗剤及び降圧剤の治療的組み合わせ
US8247456B2 (en) 2005-03-22 2012-08-21 Repros Therapeutics Inc. Dosing regimes for trans-clomiphene
CA2617905A1 (en) 2005-08-05 2007-02-15 Repros Therapeutics Inc. Methods and compositions for treating female infertility using clomiphene
EP1829534A1 (en) 2006-03-02 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Use of compounds binding to the sigma receptor for the treatment of metabolic syndrome
MY150082A (en) * 2007-10-16 2013-11-29 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
US20100111901A1 (en) * 2008-11-03 2010-05-06 Auspex Pharmaceuticals, Inc. Triazole inhibitors of aromatase
TWI458478B (zh) 2008-11-07 2014-11-01 Repros Therapeutics Inc 用於代謝症候群與第２型糖尿病的反式氯米芬
US20100144687A1 (en) * 2008-12-05 2010-06-10 Glaser Rebecca L Pharmaceutical compositions containing testosterone and an aromatase inhibitor
WO2013020215A1 (en) 2011-08-09 2013-02-14 Adams Kenneth W Use of aromatase inhibitor or estrogen blocker for increasing spermatogenesis or testosterone levels in males

Also Published As

Publication number Publication date
KR20040013131A (ko) 2004-02-11
RU2004100535A (ru) 2005-06-10
KR100851648B1 (ko) 2008-08-13
US20040097597A1 (en) 2004-05-20
US7368480B2 (en) 2008-05-06
JP2005520779A (ja) 2005-07-14
EP1411916A4 (en) 2005-08-17
CY1108563T1 (el) 2014-04-09
ZA200400142B (en) 2006-02-22
US7759360B2 (en) 2010-07-20
CN1289075C (zh) 2006-12-13
US20160354325A1 (en) 2016-12-08
ECSP044937A (es) 2004-04-28
CN1551765A (zh) 2004-12-01
HK1071521A1 (en) 2005-07-22
NZ530491A (en) 2007-08-31
CA2453337C (en) 2012-08-28
EP1411916B1 (en) 2008-08-27
CA2453337A1 (en) 2003-01-23
JP2009280623A (ja) 2009-12-03
NZ551013A (en) 2008-04-30
US20140093560A1 (en) 2014-04-03
US20150265553A1 (en) 2015-09-24
JP4845165B2 (ja) 2011-12-28
US20100286281A1 (en) 2010-11-11
PL374121A1 (en) 2005-10-03
WO2003005954A2 (en) 2003-01-23
PT1411916E (pt) 2008-12-10
BR0211067A (pt) 2006-10-31
ES2312593T3 (es) 2009-03-01
CA2777199A1 (en) 2003-01-23
US8618176B2 (en) 2013-12-31
CL2004000026A1 (es) 2005-02-04
CO5550428A2 (es) 2005-08-31
WO2003005954A3 (en) 2003-10-23
CN1954807A (zh) 2007-05-02
US20040241224A1 (en) 2004-12-02
US10561624B2 (en) 2020-02-18
EP1411916A2 (en) 2004-04-28
RU2297218C2 (ru) 2007-04-20
PL211339B1 (pl) 2012-05-31
AU2002318225B2 (en) 2007-12-13
MXPA04000097A (es) 2004-05-21
WO2003005954B1 (en) 2003-12-04
DE60228583D1 (de) 2008-10-09
ATE406153T1 (de) 2008-09-15

Similar Documents

Publication Publication Date Title
DK1411916T3 (da) Fremgangsmåder og materialer til behandling af testosteronmangel hos mænd
DK1261368T3 (da) Tværbunden, ikke-fungal lipaseholdig sammensætning og fremgangsmåder til anvendelse deraf
DE60134764D1 (de) VERWENDUNG VON MoO3 ALS KORROSIONSINHIBITOR SOWIE EINEN SOLCHEN INHIBITOR ENTHALTENDE BESCHICHTUNGSZUSAMMENSETZUNG
ATE313326T1 (de) VERWENDUNG VON CABERGOLIN ZUR BEHANDLUNG VON ßRESTLESS LEGS SYNDROMß
ATE424413T1 (de) Analoge des glucagon-ähnlichen peptids-1
DE60139429D1 (de) Pyrimidin-5-Onderivate als LDL-PLA2 Inhibitoren
CY1105009T1 (el) Συνθεση καχαλαλιδης f
DE60237311D1 (de) Photostabile sonnenschutzzusammensetzungen und stabilisierungsverfahren von dibenzoylmethan
DE69918871D1 (de) Zementzusatzmittel und Zementzusammensetzung
DE60231636D1 (de) Neue difunktionelle fotoinitiatoren
ATE460923T1 (de) Lyophilisierung von virosomen
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
DE60219068D1 (de) Substituierte 2-amino-zykloalkankarboxamide und ihre verwendung als zysteinprotease-inhibitoren
DE69915310D1 (de) Methoden zur behandlung der salzabhängigen hypertonie
DK1441761T3 (da) Fremgangsmåder til forebyggelse og behandling af flavivirus-infektion hos dyr
SE0302361D0 (sv) Inhibering av upptagning av monoamin
BR0206917A (pt) Uso de antagonistas de mglur5 para o tratamento de condições prurìticas
ATE526056T1 (de) Igf-2 peptid zur verwendung in einer tolerogenen behandlung für typ i diabetes
DE60125212D1 (de) Verwendung von Aivlosin zur Behandlung und Prevention der Lawsonia-Infektionen in Schweinen.
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs
TR201900241T4 (tr) Vasoprotektif maddelerin kombinasyonları ve bunları içeren formülasyonlar.
DE60221331D1 (de) Verwendung von 4-Ethyloctanal in Riech- und Geschmackzusammensetzungen
DE69732784D1 (de) Inhibierung von invasiver remodulierung
DK1207898T3 (da) Behandling af konjunktivitis med histacalin-proteiner
DE60232512D1 (de) Verwendung von streulichtmessungen zur abbildung des ätzvorganges in echtzeit